Sanofi (ENXTPA:SAN) Valuation Check After Recent Share Price Weakness
Sanofi (ENXTPA:SAN) shares have been drawing attention after recent performance data, with the stock showing a 1 day return of 0.5% and a 1 year total return decline of 9.2%.
See our latest analysis for Sanofi.
At a share price of €82.32, Sanofi’s relatively soft 30 day share price return of a 3.15% decline and 1 year total shareholder return of a 9.2% decline indicate that recent momentum has weakened.
If you are looking beyond big pharma for more ideas, this could be a useful time to scan other healthcare stocks that might fit your portfolio’s risk and return preferences.
With Sanofi trading at €82.32 and the provided model suggesting an intrinsic value at a significant discount, the key question is simple: is the market offering you mispriced quality here, or already baking in future growth?
Most Popular Narrative: 21.5% Undervalued
With Sanofi closing at €82.32 against a narrative fair value of about €104.87, the current price sits well below that implied level.
Sanofi's ongoing focus on innovative product launches and its strong R&D pipeline, highlighted by accelerating investments, multiple Phase III readouts through 2026, and continued expansion of biologics (e.g., Dupixent, amlitelimab), is viewed as positioning the company to capture higher demand for chronic disease treatments in a world with an aging population, which the narrative links to robust long-term sales growth and EPS upside. (Revenue, EPS)
Curious what kind of revenue path, margin uplift, and future P/E this narrative assumes to reach that fair value gap? The underlying projections may surprise you.
Result: Fair Value of €104.87 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on successful pipeline delivery and cost control, as pricing pressure and possible R&D setbacks are both capable of quickly challenging that underpriced quality story.
Find out about the key risks to this Sanofi narrative.
Build Your Own Sanofi Narrative
If you see the setup differently or simply prefer to work through the numbers yourself, you can build a personalised Sanofi view in under three minutes by starting with Do it your way.
A good starting point is our analysis highlighting 6 key rewards investors are optimistic about regarding Sanofi.
Looking for more investment ideas?
Before you move on, give yourself the chance to spot a few more opportunities using the Simply Wall Street Screener so you are not relying on a single idea.
- Target reliable cash returns by scanning these 14 dividend stocks with yields > 3% that may suit an income focused portfolio.
- Catch emerging opportunities early by filtering for these 3564 penny stocks with strong financials that line up with your risk tolerance.
- Zero in on possible mispricings by tracking these 870 undervalued stocks based on cash flows that could complement your current holdings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com